INCR vs. TEVA

Last updated Apr 2, 2026

Compare and contrast key facts about INC Research Holdings Inc (INCR) and Teva Pharmaceutical Industries Limited (TEVA).

Performance

INCR vs. TEVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in INC Research Holdings Inc (INCR) and Teva Pharmaceutical Industries Limited (TEVA). The values are adjusted to include any dividend payments, if applicable.

INCR vs. TEVA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
INCR INC Research Holdings Inc	-15.01%	-42.77%	23.27%	-60.92%	-49.07%	-4.00%
TEVA Teva Pharmaceutical Industries Limited	-3.08%	41.61%	111.11%	14.47%	13.86%	-14.61%

Fundamentals

Market Cap INCR : $43.93M TEVA : $35.48B
EPS INCR : -$1.25 TEVA : $1.21
PS Ratio INCR : 0.18 TEVA : 2.04
PB Ratio INCR : 0.10 TEVA : 4.48
Total Revenue (TTM) INCR : $243.12M TEVA : $17.26B
Gross Profit (TTM) INCR : $40.61M TEVA : $8.94B
EBITDA (TTM) INCR : -$79.49M TEVA : $3.80B

Returns By Period

In the year-to-date period, INCR achieves a -15.01% return, which is significantly lower than TEVA's -3.08% return.

INCR

• 1D: 3.00%
• 1M: -8.97%
• YTD: -15.01%
• 6M: -53.13%
• 1Y: -43.55%
• 3Y*: -27.62%
• 5Y*: —
• 10Y*: —

TEVA

• 1D: 0.43%
• 1M: -10.42%
• YTD: -3.08%
• 6M: 50.80%
• 1Y: 97.84%
• 3Y*: 50.64%
• 5Y*: 21.38%
• 10Y*: -5.21%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

INCR vs. TEVA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

INCR

INCR Risk / Return Rank: 8
INCR Sharpe Ratio Rank: 6
INCR Sortino Ratio Rank: 6
INCR Omega Ratio Rank: 9
INCR Calmar Ratio Rank: 13
INCR Martin Ratio Rank: 6

TEVA

TEVA Risk / Return Rank: 92
TEVA Sharpe Ratio Rank: 93
TEVA Sortino Ratio Rank: 92
TEVA Omega Ratio Rank: 91
TEVA Calmar Ratio Rank: 92
TEVA Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

INCR vs. TEVA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for INC Research Holdings Inc (INCR) and Teva Pharmaceutical Industries Limited (TEVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	INCR	TEVA	Difference
Sharpe ratio Return per unit of total volatility	-0.91	2.33	-3.24
Sortino ratio Return per unit of downside risk	-1.36	3.11	-4.47
Omega ratio Gain probability vs. loss probability	0.85	1.42	-0.57
Calmar ratio Return relative to maximum drawdown	-0.77	4.44	-5.22
Martin ratio Return relative to average drawdown	-1.63	12.93	-14.56
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

INCR vs. TEVA - Sharpe Ratio Comparison

The current INCR Sharpe Ratio is -0.91, which is lower than the TEVA Sharpe Ratio of 2.33. The chart below compares the historical Sharpe Ratios of INCR and TEVA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	INCR	TEVA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.91	2.33	-3.24
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.50	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.11	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.59	0.31	-0.90

Correlation

The correlation between INCR and TEVA is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

INCR vs. TEVA - Dividend Comparison

Neither INCR nor TEVA has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
INCR INC Research Holdings Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
TEVA Teva Pharmaceutical Industries Limited	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.88%	3.19%	1.77%

Drawdowns

INCR vs. TEVA - Drawdown Comparison

The maximum INCR drawdown since its inception was -91.57%, roughly equal to the maximum TEVA drawdown of -90.89%. Use the drawdown chart below to compare losses from any high point for INCR and TEVA.

Drawdown Indicators

	INCR	TEVA	Difference
Max Drawdown Largest peak-to-trough decline	-91.57%	-90.89%	-0.68%
Max Drawdown (1Y) Largest decline over 1 year	-57.80%	-21.79%	-36.01%
Max Drawdown (5Y) Largest decline over 5 years	—	-43.70%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-88.71%	—
Current Drawdown Current decline from peak	-91.07%	-55.29%	-35.78%
Average Drawdown Average peak-to-trough decline	-64.44%	-31.90%	-32.54%
Ulcer Index Depth and duration of drawdowns from previous peaks	27.46%	7.49%	+19.97%

Volatility

INCR vs. TEVA - Volatility Comparison

The current volatility for INC Research Holdings Inc (INCR) is 8.73%, while Teva Pharmaceutical Industries Limited (TEVA) has a volatility of 11.82%. This indicates that INCR experiences smaller price fluctuations and is considered to be less risky than TEVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	INCR	TEVA	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.73%	11.82%	-3.09%
Volatility (6M) Calculated over the trailing 6-month period	36.31%	27.30%	+9.01%
Volatility (1Y) Calculated over the trailing 1-year period	48.28%	42.20%	+6.08%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.35%	42.76%	+21.59%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.35%	47.20%	+17.15%

Financials

INCR vs. TEVA - Profitability Comparison

The chart below illustrates the profitability comparison between INC Research Holdings Inc and Teva Pharmaceutical Industries Limited over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

INCR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, INC Research Holdings Inc reported a gross profit of 20.11M and revenue of 65.01M. Therefore, the gross margin over that period was 30.9%.

TEVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 2.66B and revenue of 4.71B. Therefore, the gross margin over that period was 56.4%.

INCR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, INC Research Holdings Inc reported an operating income of 2.86M and revenue of 65.01M, resulting in an operating margin of 4.4%.

TEVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported an operating income of 1.27B and revenue of 4.71B, resulting in an operating margin of 26.9%.

INCR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, INC Research Holdings Inc reported a net income of -852.00K and revenue of 65.01M, resulting in a net margin of -1.3%.

TEVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported a net income of 480.00M and revenue of 4.71B, resulting in a net margin of 10.2%.